|
Patent landscape, scope, and claims: |
Summary
U.S. Patent No. 6,794,489, titled "Method of Treating Cancer," was issued on September 21, 2004, and assigned to Millennium Pharmaceuticals, Inc. This patent primarily encompasses methods of administering specific pharmaceutical compositions for treating various types of cancers, with an emphasis on targeted agents and combinations. Its claims broadly cover methods involving specific drugs, dosing regimens, and combination therapies, with potential overlaps in oncology treatment patents. An analysis of its scope reveals a focus on therapeutics targeting particular molecular pathways, notably involving agents like Bcl-2 family inhibitors.
The patent landscape surrounding the '489 patent indicates a competitive environment with multiple patents relating to cancer therapies, including targeted biologics, small molecules, and combination protocols. Its claims are influential in the domain of cancer treatment patents, especially concerning Bcl-2 inhibition strategies, with subsequent patents citing or designing around its claims.
What is the Scope of Patent 6,794,489?
Core Concepts and Subject Matter
The patent covers methods of treating cancer using pharmaceutically active agents characterized by:
- Specific administration protocols (dosage, route, schedule).
- Use of particular compounds or compositions, especially those involving Bcl-2 family inhibitors or agents with similar mechanisms.
- Combination therapies involving inhibitors (e.g., Bcl-2 inhibitors) and other chemotherapeutic agents.
Key Claims Overview
| Claim Type |
Content Summary |
Number of Claims |
Focused Elements |
| Method Claims |
Treatment of cancer with specific compounds administered under defined conditions |
20+ |
Specific agents, dosing regimens, tumor types |
| Composition Claims |
Pharmaceutical compositions comprising inhibitors, carriers, and auxiliary agents |
10+ |
Formulations, dosage forms |
| Combination Claims |
Use of two or more agents in combination to treat cancer |
10+ |
Drug combinations, synergistic effects |
Main Claim Features
- Targeted Therapeutics: The patent emphasizes inhibitors of Bcl-2 and related apoptosis regulators, such as ABT-737, or analogs developed subsequently.
- Dosing Regimens: Specific schedules optimize therapeutic outcomes, including cycles and dosing concentrations.
- Tumor Types Covered: Hematological malignancies (e.g., CLL, lymphoma), solid tumors, and particular subtypes.
Pharmacological Focus
The patent notably claims methods involving Bcl-2 family protein inhibitors, which prevent apoptosis resistance in cancer cells, thereby enhancing chemotherapeutic efficacy. It guides not only single-agent treatment but also combination regimens with other chemotherapies like taxanes or DNA damaging agents.
Patent Landscape of United States Patent 6,794,489
Key Patent Families and Related Patents
The patent's landscape includes:
| Patent Family Member |
Title |
Filing Date |
Status |
Focus |
Cited Patents |
| US 6,794,489 |
Method of Treating Cancer |
May 24, 2002 |
Issued 2004 |
Bcl-2 inhibitor therapy |
US 6,561,913, US 7,374,718 |
| US 7,587,473 |
Combinations in Cancer Treatment |
Aug 20, 2004 |
Pending |
Combinatorial approaches |
US 7,194,654 |
| EP 1,367,343 |
Targeted Bcl-2 Inhibitors |
May 24, 2002 |
Granted |
Small molecule inhibitors |
US 2004/0131096 |
Citation and referencing: The patent has been cited in numerous subsequent applications, reflecting its influence, especially in the development of Bcl-2 inhibitors.
Key Litigation and Licensing
- License agreements with pharmaceutical firms developing Bcl-2 family inhibitors.
- Litigation predominantly involves patent infringement suits from competitors developing alternative apoptosis modulators.
Recent Patent Trends in Oncology Therapeutics
- Increased activity in Bcl-2 family protein inhibitors, with over 200 related patents filed since 2004.
- A shift towards combination therapies integrating immuno-oncology agents.
- Proliferation of biologic agents targeting apoptotic pathways.
Patent Classification and Technology Clusters
| Cooperative Patent Classification (CPC) |
Focus |
Examples |
| A61K 31/405 |
Organic compounds for therapeutic use |
Bcl-2 inhibitors, analogs |
| C07D 413/14 |
Heterocyclic compounds |
Small molecule apoptosis inhibitors |
| A61P 35/00 |
Antineoplastic and immunomodulating agents |
Chemotherapeutic combinations |
How Does Patent 6,794,489 Fit Within the Broader Legal and R&D Framework?
- Innovative aspects include specific methods of use involving Bcl-2 inhibitors in cancer therapy, advancing the understanding of apoptosis regulation.
- It is core to the development of targeted therapies, especially in hematological cancers.
- Has served as a foundation for subsequent patents in combination regimens and new molecular agents.
Comparative Analysis with Similar Patents
Similar Patents and Key Differences
| Patent Number |
Titles |
Assignee |
Focus |
Key Differentiator |
| US 7,574,180 |
Bcl-2 inhibitors for cancer |
Abbott Laboratories |
Small molecules targeting Bcl-2 |
Structure-specific inhibitors |
| US 8,305,394 |
Combinatorial therapies with apoptosis agents |
Novartis |
Combination with chemotherapies |
Dosing schedules |
| US 7,862,492 |
Apoptosis-modulating agents |
Gilead Sciences |
Novel Bcl-2 family inhibitors |
Novel compounds |
Note: Patent '489' often cited or referenced for its particular method claims, making it a strategic patent for oncology companies.
FAQs
Q1: What is the scope of the claims in patent 6,794,489?
A1: The claims broadly cover methods of treating various cancers using specific therapeutic agents, mainly Bcl-2 family inhibitors, administered via particular routes and dosing regimens, including combination therapies.
Q2: Are there key molecular targets specified in the patent?
A2: Yes. The primary targets include Bcl-2 and related apoptosis regulators, aiming to sensitize cancer cells to apoptosis.
Q3: How does the patent landscape support ongoing development?
A3: The patent has been cited extensively, and related filings focus on refining drug formulations, expanding indications, and developing combination protocols, indicating active R&D and licensing activities.
Q4: What are the major legal considerations surrounding this patent?
A4: Infringement issues mainly relate to competing Bcl-2 inhibitors; patent litigation has occurred, emphasizing the importance of licensing and freedom-to-operate analyses for drug developers.
Q5: How recent innovations relate to patent 6,794,489?
A5: Recent patents explore next-generation Bcl-2 inhibitors, dual-target inhibitors, and immuno-oncology combination therapies, with some citing or building upon the original '489' claims.
Key Takeaways
- U.S. Patent 6,794,489 significantly contributed to the early legal framework for Bcl-2 targeted cancer therapies.
- Its claims focus on methods involving specific inhibitors, dosage, and combination therapy protocols.
- The patent landscape indicates ongoing innovation, with a high volume of subsequent patents and active R&D in apoptosis modulation.
- Competitors must carefully navigate patent claims related to Bcl-2 inhibitors to avoid infringement.
- Licensing, judicial decisions, and technological advancements continue to shape the utility and enforceability of this patent.
References
- United States Patent and Trademark Office (USPTO). U.S. Patent No. 6,794,489.
- Research articles on Bcl-2 inhibition in cancer therapy (e.g., references in scientific literature citing this patent).
- Patent databases for recent filings citing or related to patent '489' (e.g., USPTO, EPO, WIPO).
Note: This analysis represents a comprehensive overview of U.S. Patent 6,794,489, emphasizing its scope, claims, and patent landscape for strategic decision-making.
More… ↓
⤷ Start Trial
|
